|
KMID : 1142020220570000120
|
|
Blood Research
2022 Volume.57 No. 0 p.120 ~ p.129
|
|
|
Treatment of indolent lymphoma
|
|
Jeong Seong-Hyun
|
|
|
Abstract
|
|
|
|
Treatment of indolent lymphoma has improved significantly in recent decades since the advent of rituximab (anti-CD20 monoclonal antibody). Although, some patients with limited disease can be cured with radiation therapy alone, most patients experience disease progression and recurrence during follow-up despite early initiation of treatment. Thus, watch-and-wait is still regarded the standard for asymptomatic patients. Patients with indolent lymphoma have a significant heterogeneity in terms of tumor burden, symptoms (according to anatomical sites) and the need for instant therapy. Therefore, the initiation of treatment and treatment option should be decided with a clear goal in each patient according to the need for therapy and clinical benefits with the chosen treatment. In this review, we cover the current treatment of follicular lymphoma and marginal zone lymphoma.
|
|
|
KEYWORD
|
|
|
Indolent lymphoma, Non-Hodgkin’s lymphoma, Follicular lymphoma, Marginal zone lymphoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|